Novo Nordisk A/S is a finished-dose manufacturer based in Denmark. It appears in 2,748 regulatory filings across 41 regulators, without an active US DMF or CEP on file. Its filings concentrate with AIFA (IT), FAMHP (BE) and MHRA (UK). Its GMP standing is certified by ANVISA (Brazil), NCELS (KZ) and NAFDAC (NG), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 4 May 2023 as VAI. Customs aggregates show $21K of exports covering 3,719 molecules to 8 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Bagsvaerd, United Arab Emirates | Not on file |
| Bagsvaerd, United Arab Emirates | Not on file |
| Gentofte, United Arab Emirates | Not on file |
| Hjoerring, United Arab Emirates | Not on file |
| MALØV, Denmark | Not on file |
| Bagsvaerd, Denmark | Not on file |
6 further sites are on record.
| Regulator | Filings | GMP certificates |
|---|---|---|
| AIFA (IT) | 356 | None |
| FAMHP (BE) | 323 | None |
| MHRA (UK) | 299 | None |
| Health Canada | 250 | None |
| EMA | 209 | 1 |
| INFARMED (PT) | 203 | None |
| ANVISA (Brazil) | None | 9 |
| NCELS (KZ) | None | 4 |
| NAFDAC (NG) | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2025 | Not reported | $21K | 8 |
| 2024 | Not reported | $25K | 7 |
| 2023 | $610.0B | $24K | 7 |
| 2022 | $500.0B | $2K | 4 |
| 2021 | $380.0B | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Novo Nordisk A/S comes back tiered against every other supplier able to file there.
Start for free